Reduced Costs and Continued Cures Act

Summary

Reduced Costs and Continued Cures Act This bill establishes and alters several programs and requirements relating to the prices of prescription drugs. For example, the bill establishes and alters several requirements under Medicare and Medicaid, including requiring drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation, capping annual out-of-pocket spending under the Medicare prescription drug benefit, and increasing the maximum rebate amount under the Medicaid Drug Rebate Program. The bill also makes changes relating to market exclusivities and manufacturer price concessions for prescription drugs, including authorizing the Federal Trade Commission to initiate proceedings against parties to settlements of patent infringement claims that have anticompetitive effects with respect to drugs or biologics, limiting in certain instances the number of patents that the manufacturer of a biologic can assert in a lawsuit against a company seeking to sell a biosimilar version, and nullifying regulations relating to the treatment of certain Medicare prescription drug benefit rebates from drug manufacturers for purposes of federal anti-kickback laws.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 14 September 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

2. 14 September 2021

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

3. 14 September 2021

   Introduced

   Introduced in House

   Source: IntroReferral

4. 14 September 2021

   Introduced

   Introduced in House

   Source: IntroReferral

5. 15 September 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

6. 1 November 2022

   Referred

   Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 14 September 2021 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 14 September 2021

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 14 September 2021

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 14 September 2021

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Peters, Scott H. [D-CA-50] · D · Sponsor
• Rep. Schrader, Kurt [D-OR-5] · D · Sponsor
• Rep. Rice, Kathleen M. [D-NY-4] · D · Sponsor
• Rep. Murphy, Stephanie N. [D-FL-7] · D · Sponsor
• Rep. Correa, J. Luis [D-CA-46] · D · Sponsor
• Rep. Gottheimer, Josh [D-NJ-5] · D · Cosponsor
• · hsju00 · Standing
• · hsif00 · Standing
• · hswm00 · Standing

Related records

• related to → Freedom from Price Gouging Act
• related to → Star Rating for Biosimilars Act
• related to → Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
• related to → Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
• related to → Preserve Access to Affordable Generics and Biosimilars Act
• related to → Capping Drug Costs for Seniors Act of 2021
• related to → Preserve Access to Affordable Generics and Biosimilars Act
• related to → Affordable Prescriptions for Patients Act of 2021

Showing 8 of 10 related records.